CN106456764A8 - 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 - Google Patents

用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 Download PDF

Info

Publication number
CN106456764A8
CN106456764A8 CN201580028585.0A CN201580028585A CN106456764A8 CN 106456764 A8 CN106456764 A8 CN 106456764A8 CN 201580028585 A CN201580028585 A CN 201580028585A CN 106456764 A8 CN106456764 A8 CN 106456764A8
Authority
CN
China
Prior art keywords
pdl
antagonist
hpv negative
treating hpv
negative cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580028585.0A
Other languages
English (en)
Other versions
CN106456764A (zh
Inventor
K.斯特尔
M.C.雷贝拉托
J.A.巴拉克-哈斯金斯
P.B.罗宾斯
J.R.瓦塞利
R.A.斯图尔特
R.伊布拉希姆
A.沙拉比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN106456764A publication Critical patent/CN106456764A/zh
Publication of CN106456764A8 publication Critical patent/CN106456764A8/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

在此提供的是治疗HPV阴性肿瘤的方法,该方法包括给予有效量的PDL-1/PD-1相互作用的拮抗剂(例如,抗PDL-1或抗PD-1抗体或其抗原结合片段)。
CN201580028585.0A 2014-05-29 2015-05-28 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 Pending CN106456764A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004731P 2014-05-29 2014-05-29
US62/004,731 2014-05-29
PCT/EP2015/061909 WO2015181331A1 (en) 2014-05-29 2015-05-28 Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers

Publications (2)

Publication Number Publication Date
CN106456764A CN106456764A (zh) 2017-02-22
CN106456764A8 true CN106456764A8 (zh) 2017-06-30

Family

ID=53276122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580028585.0A Pending CN106456764A (zh) 2014-05-29 2015-05-28 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂

Country Status (13)

Country Link
US (1) US20160031990A1 (zh)
EP (1) EP3149043A1 (zh)
JP (1) JP2017517525A (zh)
KR (1) KR20170007750A (zh)
CN (1) CN106456764A (zh)
AU (1) AU2015265859A1 (zh)
BR (1) BR112016027881A2 (zh)
CA (1) CA2949327A1 (zh)
IL (1) IL248836A0 (zh)
RU (1) RU2016151757A (zh)
SG (1) SG11201609468WA (zh)
TW (1) TW201625300A (zh)
WO (1) WO2015181331A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104479018B (zh) 2008-12-09 2018-09-21 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CA2932966C (en) 2013-12-12 2022-03-22 Shanghai Hengrui Pharmaceutical Co., Ltd. Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
EP3268392A2 (en) 2015-03-13 2018-01-17 CytomX Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
RS61532B1 (sr) * 2015-07-14 2021-04-29 Bristol Myers Squibb Co Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
PE20191102A1 (es) 2016-09-14 2019-08-23 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11813279B2 (en) * 2018-12-21 2023-11-14 Aim Immunotech Inc. Compositions for cancer therapy and methods
US20230068783A1 (en) * 2020-01-21 2023-03-02 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101740171B1 (ko) * 2009-11-24 2017-05-25 메디뮨 리미티드 B7―h1에 대한 표적화된 결합 물질
MY186099A (en) * 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2015034519A1 (en) * 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
HUE046674T2 (hu) * 2013-09-11 2020-03-30 Medimmune Ltd B7-H1 elleni antitestek tumorok kezelésére

Also Published As

Publication number Publication date
BR112016027881A2 (pt) 2017-10-24
US20160031990A1 (en) 2016-02-04
TW201625300A (zh) 2016-07-16
WO2015181331A1 (en) 2015-12-03
CA2949327A1 (en) 2015-12-03
KR20170007750A (ko) 2017-01-20
JP2017517525A (ja) 2017-06-29
CN106456764A (zh) 2017-02-22
SG11201609468WA (en) 2016-12-29
IL248836A0 (en) 2017-01-31
RU2016151757A (ru) 2018-07-02
AU2015265859A1 (en) 2016-12-15
EP3149043A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
CN106456764A8 (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
MX2022002364A (es) Anticuerpos anti-pd-l1.
WO2016014688A3 (en) Anti-pd-1 antibodies
WO2016062722A8 (en) Combination
WO2018093821A8 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
EP3604337A4 (en) B7-H3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THE SAME, AND ITS MEDICAL USE
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
EP4324518A3 (en) Antibody molecules to tim-3 and uses thereof
EP3552665A3 (en) Antibodies
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12016501366A1 (en) Novel anti-baff antibodies
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
EA201792058A1 (ru) Виротерапия комбинацией антител
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
EP3730519A4 (en) ANTIBODY OR ANTIGENT BINDING FRAGMENT THEREOF FOR THE SPECIFIC DETECTION OF B-CELL MALIGNOMAS, CHIMERA ANTIGEN RECEPTOR THEREOF AND USE THEREOF
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
EP3401336A4 (en) PCSK9 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USES THEREOF
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 62/004,731 2014.05.29 US

Number: 08

Volume: 33

CI01 Publication of corrected invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 62/004,731 2014.05.29 US

Number: 08

Page: The title page

Volume: 33

CI02 Correction of invention patent application
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222

WD01 Invention patent application deemed withdrawn after publication